34 results about "Tolerability" patented technology

This invention relates to antibody-drug conjugates and their uses. An antibody-drug conjugate having a structure represented by formula (I) is provided: Ab-(L-D) n (I), wherein Ab is an antibody against the interleukin-6 receptor or an antigen-binding fragment thereof, said antibody or antigen-binding fragment comprising at least one light chain and at least one heavy chain as described herein, and the use of the antibody-drug conjugate. The antibody-drug conjugate of the present invention can significantly reduce the dosage, improve patient tolerability, and reduce adverse reactions.

Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.

To provide a combination for gastric cancer therapy which brings about enhanced therapeutic effects and reduced side effects.SOLUTION: Gastric cancer patients treated daily with the combination of the minelide prodrug and paclitaxel experienced significant negative side effects and cancer progression. Combination therapy of paclitaxel with a minelide prodrug administered according to the new regimen resulted in significantly improved therapeutic outcomes. The new dosing regimen comprises a 28-day cycle in which the minelide prodrug is administered once daily on days 1-5, 8-12, and 15-19 of the cycle, and paclitaxel is administered once daily on days 1, 8, and 15 of the cycle. The new dosing regimen was shown to be effective for treating gastric cancer and well tolerated in human patients.SELECTED DRAWING: Figure 5A

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for preventing or treating progressive hearing loss of large vestibular aqueduct syndrome as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from fructus psoraleae, herba cistanche, rhizoma drynariae, poria peel, polyporus umbellatus, cortex mori radicis, plantain herb, radix salviae miltiorrhizae, ligusticum wallichii, caulis spatholobi and honey-fried licorice root. The traditional Chinese medicine composition disclosed by the invention has the effects of tonifying kidney and strengthening primordial qi, and tonifying spleen and promoting urination, and is mainly used for preventing or treating patients with progressive hearing loss caused by large vestibular aqueduct syndrome. Compared with western medicine glucocorticoid, the traditional Chinese medicine composition has no adverse reaction, the health risk is reduced, and the treatment tolerance and compliance of patients are improved. A standardized scheme for preventing or treating progressive hearing loss of large vestibular aqueduct syndrome by traditional Chinese medicine is formed, clinical popularization is facilitated, more patients are benefited, a reference basis is provided for subsequent research, and related medical research is promoted.

Intravesical devices are provided that are wholly deployable within the bladder of a patient in need of treatment and are well tolerated by the patient. The device may include an elastic body having a retention shape having (i) dimensions that provide intravesical mobility and that prevent voiding of the medical device through the urethra, and (ii) dimensions, buoyancy, or both, that exclude the medical device from entering the orifices of the ureters. The elastic body may exert a maximum acting force less than 1 N when compressed to a shape with a maximum dimension in any dimension of 3 cm. The device may include a drug for controlled release within the bladder, for treatment of the bladder or a regional tissue. Methods of treatment are also provided that include selecting a patient in need of treatment in the bladder where tolerability of the treatment is a primary concern.

The invention discloses application of licoflavone A in resisting viral hepatitis B, and belongs to the technical field of medicine application. The licoflavone A is used for treating viral hepatitis B. The licoflavone A used in the invention shows good safety and tolerance in HepG2.2. 15 and HepG2.A64 cells, can play a role in resisting HBV under the condition of no obvious cytotoxicity, and has significant advantages compared with interferon drugs in the prior art with long treatment course, large side effect and poor tolerance.

The invention relates to an effect of limited uptake of arachidonic acid (AA) in preparation of a chemotherapy sensitizer, and particularly relates to an application of the arachidonic acid (AA) in preparation of the chemotherapy sensitizer. A large number of researches find that the AA content is extremely related to the colorectal cancer chemotherapy resistance, the high level of AA has negative correlation with the colorectal cancer chemotherapy sensitivity, the AA can be used for predicting the colorectal cancer chemotherapy tolerance and sensitivity degree, and early evaluation is provided for the relation of preoperative treatment of a patient. Meanwhile, AA uptake is limited, for example, AA transporter SLC27A4 is inhibited, an important function of colorectal cancer chemotherapy sensitization is achieved, correspondingly, the tolerance of a patient to colorectal cancer chemotherapy can be reduced by reducing the level of AA in a body, the chemotherapy treatment effect is improved, the survival rate of the patient is prolonged, and prognosis is improved. The invention provides sufficient scientific basis and theoretical basis for exploring new colorectal cancer diagnosis, prognosis judgment and treatment molecular targets and developing new targeted drugs, is helpful for better realizing accurate treatment, and has important social value and scientific significance.

The invention relates to an application of osimertinib combined with chidamide in treatment of osimertinib drug-resistant lung cancer, and particularly relates to the following aspects: (1) osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and shows a remarkable curative effect in treatment of non-small cell lung cancer (NSCLC) patients carrying specific EGFR mutation; (2) chidamide is a novel oral HDACi, can induce cell apoptosis, cell cycle arrest and cell growth inhibition, and shows good tolerance and antitumor activity in various cancer types; and (3) chidamide is taken as an epigenetic regulating agent and can be in synergistic effect with osimertinib, so that the capability of killing lung cancer cells is enhanced. The invention belongs to the technical field of medicines, and particularly provides application of osimertinib combined with chidamide in treatment of osimertinib drug-resistant lung cancer.

The application provides a traditional Chinese medicine external application method for reducing the risk of fistula fibrosis in dialysis patients, relates to the technical field of clinical application of traditional Chinese medicine, is suitable for the prevention of autologous arteriovenous fistula fibrosis of maintenance hemodialysis patients, can effectively reduce the incidence of complications such as fistula peripheral tissue fibrosis and vascular stenosis, and prolongs the service life of the fistula. The drug stability and skin permeability are improved through optimization of adjuvants, and based on the grouping intervention of maintenance hemodialysis patients, the fistula blood flow and fibrosis improvement are evaluated in combination with color Doppler ultrasound. The application takes the principles of promoting blood circulation to remove blood stasis, dredging collaterals and resolving knots, and detoxification and swelling reduction as the therapeutic principles, prepares a fistula protection ointment by screening and optimizing a traditional Chinese medicine formula, realizes the effects of improving local microcirculation of the fistula, inhibiting fibrous tissue proliferation and reducing inflammatory reactions through external application intervention, thereby reducing the incidence of fistula fibrosis and related complications, prolonging the fistula patency time, simultaneously reducing the treatment cost, and improving the patient tolerance and life quality.

A pharmaceutical composition comprising azilsartan medoxomil potassium and a calcium channel blocker, a method for preparing same, and use thereof are provided. Azilsartan medoxomil potassium and the calcium channel blocker are formulated into a compound formulation, thus improving the blood pressure lowering efficacy, improving safety and tolerability, and reducing adverse effects. Azilsartan medoxomil potassium can ameliorate peripheral edema caused by amlodipine by means of expanding peripheral venous vessels, while amlodipine can ameliorate adverse effects such as vasogenic edema, dry cough, and the like caused by azilsartan medoxomil potassium.

Through virtual screening based on molecular docking, molecular dynamics simulation, free energy calculation and experimental verification, it is found for the first time that benfotiamine can efficiently antagonize P2Y14R, and the IC50 value of benfotiamine reaches 0.31 nM. Experimental results show that benfotiamine can significantly relieve inflammatory reactions of a DSS-induced mouse colitis model and an MSU-induced gouty arthritis model, and the action mechanism of benfotiamine is closely related to inhibition of activation of NLRP3 inflammasomes. Benfotiamine is used as a vitamin B1 derivative clinically applied for a long time and has good safety and tolerance. The invention provides a brand new pharmacological action target and indication direction, realizes new use of old medicines, is beneficial to shortening the research and development period of medicines and reducing the development cost, and has important application prospects and economic and social values in the field of treatment of inflammatory diseases.

The present disclosure provides methods for treating or managing fibromyalgia and its associated symptoms in a subject in need hereof characterized by an early onset of one or more of: (1) a reduction in widespread pain characterized by about 0.3 or more difference in the LS mean change in the NRS Pain Score; (2) a reduction in sleep disturbance characterized by about 2.9 or more difference in the LS Mean change in PROMIS Sleep Disturbance T-score; (3) a reduction in fatigue characterized by about 2.0 or more difference in the LS Mean change in PROMIS Fatigue T-score; or (4) an improved sleep quality characterized by about 0.5 or more difference in the LS Mean change in NRS Sleep Quality Score, each as compared to placebo, comprising administering to a subject in need thereof 2.8 mg or 5.6 mg cyclobenzaprine HCl once daily in one or more dosage units by transmucosal administration. The present disclosure also provides methods for preventing or avoiding one or more of a clinically meaningful change in mean weight, a clinically meaningful change in mean systolic blood pressure or mean diastolic blood pressure, or a decline in sexual functioning in conjunction with treating or managing fibromyalgia or its associated symptoms in a subject in need thereof, the treatment or management being characterized by the transmucosal administration of cyclobenzaprine HCl in one or more dosage units (e.g., a first dosage unit or a second dosage unit). The cyclobenzaprine HCl of these methods is in the form of a mannitol eutectic (e.g., a 75% ± 2% by weight cyclobenzaprine HCl and 25% ± 2% by weight β‑mannitol eutectic) and the one or more dosage units further comprise a basifying agent.

The invention belongs to the field of medicine and health, and particularly relates to application of fresh traditional Chinese medicine radix puerariae exosome-shaped vesicles P-ELNs in medicine or health food for preventing and treating irritable bowel syndrome, the P-ELNs serving as an active ingredient can improve expression of colonic intestinal mucus protein MUC2 and tight junction protein ZO-1 and improve mucous membrane barrier integrity; the inhibition of the expression level of proinflammatory factors (such as TNF-alpha, IL-6, IL-1beta and NF-kappa B) indicates that the action mechanism may involve the synergistic effect of inflammation inhibition and barrier repair. Toxicological experiments show that the P-ELNs have no toxicity after long-term intragastric administration, have no adverse effects on heart, liver, spleen, lung and kidney functions, and have good oral safety and tissue tolerance. The indications comprise anti-inflammatory treatment of active-stage UC patients; maintenance and barrier repair of patients in the UC remission period; the UC disease course is more than or equal to 8 years, and a preventive medicine is applied to high-risk people with cancerization family history and the like; the invention relates to auxiliary treatment of UC-CAC early cancerization patients.

The invention relates to a traditional Chinese medicine composition for improving hypomenorrhea and application thereof, and belongs to the technical field of biological medicine. The herba leonuri, the anisodamine and the Dingkundan are combined to form the composition, efficacy complementation can be achieved, it is guaranteed that the medicine takes effect quickly, the long-acting treatment effect is maintained, meanwhile, the side effect caused by long-term single medication is avoided, the treatment safety and tolerance are improved, the menstrual volume can be remarkably increased, endometrial blood circulation can be improved, and the curative effect is improved. The hypomenorrhea is effectively improved. The medicines in the composition are all approved compliant medicines, the source is clear, the quality is controllable, the administration scheme is simple and easy to implement, the composition is suitable for clinical popularization and application, and a novel safe, efficient and reproducible treatment method is provided for hypomenorrhea.

A system for remote assessment of clinical response and dynamic optimization of the chemotherapy regimen in oncology, consisting of: a device for clinical assessment of patient response, designed as a physical machine structure with a housing for use on the body or at the bedside; a housing-mounted physiological sensor unit configured to record continuous or periodic measurements of heart rate, heart rate variability, respiratory rate, peripheral oxygen saturation, body temperature, physical activity and sleep-related parameters of an oncology patient during chemotherapy; a biochemical sensor unit integrated into the housing, configured to detect biochemical indicators related to response to chemotherapy and toxicity, including inflammatory markers, metabolic indicators, hematological trends or drug-related metabolites; a patient interaction unit configured to receive symptom data reported by the patient, corresponding to treatment tolerability and functional status; an embedded processing unit that is operationally connected to the physiological sensor unit, the biochemical sensor unit, and the patient interaction unit, and is configured to perform signal conditioning, temporal alignment, data integrity verification, and encryption of the acquired patient data; a communication unit that is operationally connected to the embedded processing unit and configured to transmit the processed patient data to a remote processing infrastructure using secure communication protocols; a remote processing system comprising at least one processing unit and a storage unit for storing executable instructions, wherein the processing unit is configured to aggregate longitudinal patient data across chemotherapy cycles, analyze correlations between recorded physiological data, biochemical indicators, patient-reported outcomes, and parameters of chemotherapy administration, and calculate a clinical assessment of response; and A system for interacting with physicians, configured to display the results of the clinical response assessment and generate recommendations for optimizing the chemotherapy regimen, which are subject to review and approval by the physician.

The invention provides application of beta-1, 3 / alpha-1, 3-glucan in preparation of liver cancer postoperative recovery products, and belongs to the field of medicines. The food-grade beta-1, 3 / alpha-1, 3-glucan provided by the invention is proved to be capable of remarkably reducing the tumor load after the liver cancer operation and improving the clinical remission rate, and has important clinical significance and application value. The invention provides a new strategy for postoperative recovery of liver cancer, which is high in safety and good in tolerance, and provides a new technical scheme for reducing the risk of tumor recurrence and improving postoperative patients.

The invention provides a cantharidin-alkannin derivative as well as a preparation method and application thereof, and relates to the field of drug synthesis and application, two active structures of alkannin and norcantharidin are spliced into a norcantharidin-alkannin anti-tumor monomer, the two active structures are combined to generate a synergistic anti-tumor effect, and the anti-tumor activity of the norcantharidin-alkannin anti-tumor monomer is improved. According to the present invention, with the application of the traditional Chinese medicine composition, the adverse reactions such as the improvement of the water solubility of the alkannin, the reduction of the irritation of the norcantharidin to the gastrointestinal tract and the like can be possibly reduced in the aspects of tumor cell killing effect enhancing, treatment efficiency improving and toxic-side effect reducing, such that the tolerance and the compliance of the patient are improved, and the more effective treatment scheme is provided for the cancer patient; a foundation is laid for developing a novel anti-tumor drug with the characteristics of high efficiency and low toxicity.

The inventors establish a role for primary cilia in human TNBC chemotherapeutic resistance. They developed patient-derived organoids, and showed that these recapitulated the cellular heterogeneity of TNBC biopsies. They treated their TNBC organoids with chemotherapeutics and observed partial killing. The surviving cells with organoid-reconstituting capacity showed selective enrichment for the quasi-mesenchymal ciliated cell subpopulation. They developed a family of small-molecule inhibitors of ciliogenesis and show that these, or genetic ablation of primary cilia, suppress chemoresistance. In particular, the present invention relates to a method of preventing therapeutic resistance in a patient suffering from a cancer comprising administering to the patient a therapeutically effective amount of an inhibitor of ciliogenesis. The present invention also relates to a method of treating a therapy-resistant cancer in a patient suffering from a cancer comprising administering to the patient a therapeutically effective amount of an inhibitor of ciliogenesis.

FIELD: psychology.SUBSTANCE: used in the psychocorrection of traumatic experiences. A preliminary session with a psychotherapist is held. The client is taught the 4 stages of the method. The client then begins to independently complete the stages for 7–8 minutes a day until the memory of the traumatic episode no longer evokes negative feelings. The first stage of the method “Self-regulation and preparation for working with trauma” consists of 3 sub-stages, in which the following are performed: the exercise “Attention training”, the exercise “3 pleasant experiences a day”, the exercise “The principle of the stone and the wave”, breathing techniques. The second stage of the “Systematic desensitization” method involves actualizing feelings from a traumatic memory, and then “Parasympathetic breathing” is carried out. The third stage, “Neurophysiological modeling,” involves the client imagining the desired outcome in their life by processing the memory of a traumatic experience, then choosing a simple, monotonous movement and performing it for 1–2 minutes. The fourth stage is “Identifying obstacles to achieving the desired result.”EFFECT: method enables the processing of negative traumatic memories and the accompanying relief of nervous tension, increased stress resistance, and a reduction in the impact of the traumatic event on a person's well-being, mood, self-esteem, thoughts, feelings, and behavior.3 cl

The application discloses a c-Kit (V559D) / PDGFRbeta double-target allosteric inhibitor, a preparation method, a pharmaceutical composition and application thereof, and belongs to the medical field. The inhibitor comprises a compound as shown in a general formula (I) or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof, can effectively overcome all EGFR-TKI drug resistance caused by non-genetic drug resistance mechanisms, has an anti-tumor and anticancer effect, can accurately locate specific target proteins, reduces the influence on other non-target proteins, thereby reducing off-target effects and potential toxic side effects, and improves safety and tolerability. The structure of the general formula (I) is as follows.

This invention relates to the field of intelligent control technology for medical devices, and provides a device for monitoring and relieving headache abnormalities through stimulation intervention. The device includes a helmet-shaped main frame housing a monitoring and relief module; an intelligent control system that asynchronously collects physiological characteristics and hardware load status via a duplex channel, deriving a high-dimensional state fusion model; and a closed-loop evaluation and iteration module to establish a differential efficacy closed-loop mechanism, uploading the collected data to the cloud for storage, enabling historical data management, clinical analysis, and continuous optimization of personalized strategies. This technical solution addresses the problems of dependence and side effects associated with traditional drug treatments, the high trauma and cost of surgical treatments, and the tendency of existing migraine intervention devices to develop tolerance in the nervous system due to fixed and predictable stimulation parameters used in open-loop control, leading to gradual attenuation of intervention effects over time and an inability to provide personalized and precise treatment.

This application discloses the fusion polypeptide AJ007 and its use, and belongs to the art of ophthalmic drugs. This fusion polypeptide AJ007 is formed by linking a TAT membrane-permeable peptide to the tip of a polypeptide HM-1 molecule that inhibits neovascularization. The fusion polypeptide AJ007 was used in the preparation of polypeptide eye drops, and by selecting the formulation of this application, the fusion polypeptide AJ007 was prepared as an eye drop. In the prevention or treatment of wet age-related macular degeneration, the method of administering eye drops effectively avoids various serious side effects and low patient tolerance problems associated with intravitreal injection in clinical practice, and has the advantage of non-invasive treatment. Furthermore, in a laser-induced mouse wAMD model, it showed extremely good efficacy in improving abnormal hyperplasia of choroidal neovascularization, and possesses high clinical therapeutic potential.

The invention relates to the technical field of sludge conditioners, in particular to a pharmaceutical composition for preventing and treating oropharyngeal mucosal injury caused by radiotherapy and chemotherapy, which is prepared from forsythin, radix ophiopogonis total saponins, L-glutamine, famciclovir, yeast beta-glucan, recombinant human epidermal growth factors, glutathione and glycine. The oral pharyngeal mucosal injury caused by chemoradiotherapy can be prevented and treated. According to the traditional Chinese medicine composition, multiple components have a synergistic effect, and the traditional Chinese medicine composition has prevention and treatment effects and is free of incompatibility and good in tolerance; the mucous membrane adhesive force is enhanced, the administration frequency is reduced, the dosage forms are diversified, different injury degrees and medication scenes are adapted, and the clinical prevention and control requirements are comprehensively met.

The invention relates to the technical field of artificial intelligence, and discloses an AI gait adjusting system for static sitting incapability caused by antipsychotics, comprising: a gait data acquisition module for acquiring gait motion data and multi-modal physiological behavior data of a patient; the fusion evaluation module is in communication connection with the gait data acquisition module, and is used for realizing all-directional acquisition of kinematics and multi-modal physiological behavior data through multi-module cooperation based on the gait motion data and the multi-modal physiological behavior data, and generating a quantitative state index through AI analysis, so that the evaluation is more accurate; a multi-channel and multi-dimensional comprehensive intervention system is formed, intervention is more targeted, and the relieving effect is remarkable. And on the basis of a virtual patient model and a reinforcement learning algorithm, one-person-one-strategy personalized dynamic intervention is realized, and the adaptability is higher. A non-drug intervention mode is adopted, drug dependence and new side effects are avoided, intervention measures are safe and controllable, and tolerance is good.

The use of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone in the preparation of a drug for treating peripheral T-cell lymphoma (PTCL). The PTCL is preferably treatment-naïve PTCL. Other first-line and second-line drugs for treating PTCL may also be further used on the basis of the foregoing. A method for treating PTCL, the method comprising administering, to a patient, a therapeutically effective amount of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone. The combined administration of the drugs is safe and tolerable, has a small toxicity and few side effects, and can obtain a higher total objective remission rate (ORR) in treatment-naïve PTCL patients.

The application discloses a kind of HClpP agonist compound and its purposes, specifically, the application discloses a kind of compound shown in formula I, or its pharmaceutically acceptable salt, solvate, hydrate, isomer, wherein, each group is as defined above.The compound of the application has good safety and tolerability, and can be used to agonize HClpP, treat diseases or conditions mediated by HClpP.

The application discloses a chronic disease acupuncture conditioning multi-modal fusion adaptive decision support system, which is based on traditional Chinese medicine theory and modern algorithm, constructs a whole cycle multi-modal data fusion architecture of "preoperative baseline-intraoperative real-time-postoperative interval-treatment iteration", accurately quantifies acupuncture long-term lag effect and independent intervention effect through time series mutual information, causal forest and other algorithms, builds a treatment level adaptive decision engine to realize functions such as syndrome type drift adaptation and acupoint tolerance correction, combines operation quality control closed loop and multidisciplinary collaborative optimization, solves the core pain points of the prior art, improves the accuracy, safety and accessibility of acupuncture conditioning, provides a standardized and digital solution for non-drug intervention of chronic diseases, and is suitable for whole cycle acupuncture conditioning management of various chronic diseases.